Canaccord Genuity analyst Austin Moeller maintains VSE (NASDAQ:VSEC) with a Buy and lowers the price target from $64 to $50.
Precipio Sees Q3 Revenue $4.5M Vs $4M Est.
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that Q3-2023 (unaudited) revenues have increased 28% to $4.5M from $3.5M in Q2-2023, and have more than doubled from $2.2M from Q3-2022.The
